SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Lindsay A. Uribe, Nghia Nguyen, Lily Kim, Huy N. Trinh, Christopher Wong, Clifford Wong, Long H. Nguyen, Mindie H. Nguyen, Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation, Digestive Diseases and Sciences, 2016, 61, 2, 618

    CrossRef

  2. 2
    Federica Invernizzi, Mauro Viganò, Glenda Grossi, Pietro Lampertico, The prognosis and management of inactive HBV carriers, Liver International, 2016, 36,
  3. 3
    Sarah L. Bermingham, Ralph Hughes, Elisabetta Fenu, Laura M. Sawyer, Elizabeth Boxall, Patrick T. Kennedy, Geoff Dusheiko, Grant Hill-Cawthorne, Howard Thomas, Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom, Value in Health, 2015, 18, 6, 800

    CrossRef

  4. 4
    Sarah Maylin, Jean-Marie Sire, Papa Saliou Mbaye, François Simon, Anna Sarr, Marie-Louise Evra, Fatou Fall, Jean Daveiga, Aboubakry Diallo, Jean-Marc Debonne, Loic Chartier, Muriel Vray, Short-term spontaneous fluctuations of HBV DNA levels in a Senegalese population with chronic hepatitis B, BMC Infectious Diseases, 2015, 15, 1

    CrossRef

  5. 5
    J. R. Andrade, L. D. Silva, C. M. Guimaraes, E. Bassetti-Soares, R. D. Cambraia, O. F. M. Couto, R. Teixeira, Chronic hepatitis B and liver schistosomiasis: a deleterious association, Transactions of the Royal Society of Tropical Medicine and Hygiene, 2014, 108, 3, 159

    CrossRef

  6. 6
    Inês Pita, Ana Maria Horta-Vale, Hélder Cardoso, Guilherme Macedo, Hepatitis B inactive carriers: An overlooked population?, GE Portuguese Journal of Gastroenterology, 2014, 21, 6, 241

    CrossRef

  7. 7
    G. V. Papatheodoridis, S. Manolakopoulos, A. Margariti, M. V. Papageorgiou, H. Kranidioti, A. Katoglou, G. Kontos, S. Adamidi, G. Kafiri, M. Deutsch, D. Pectasides, The usefulness of transient elastography in the assessment of patients with HBeAg-negative chronic hepatitis B virus infection, Journal of Viral Hepatitis, 2014, 21, 7
  8. 8
    Faisal M. Sanai, Mohammed A. Babatin, Khalid I. Bzeizi, Fahad AlSohaibani, Waleed Al–Hamoudi, Khaled O. Alsaad, Hadeel Al Mana, Fayaz A. Handoo, Hamad Al–Ashgar, Hamdan AlGhamdi, Abeer Ibrahim, Abdulrahman Aljumah, Abduljaleel Alalwan, Ibrahim H. AlTraif, Hussa Al–Hussaini, Robert P. Myers, Ayman A. Abdo, Accuracy of International Guidelines for Identifying Significant Fibrosis in Hepatitis B e Antigen–Negative Patients With Chronic Hepatitis, Clinical Gastroenterology and Hepatology, 2013, 11, 11, 1493

    CrossRef

  9. 9
    Claudio Puoti, How to manage HBeAg-negative chronic HBV infection with normal alanine aminotransferase levels in clinical practice?, European Journal of Internal Medicine, 2013, 24, 2, 100

    CrossRef

  10. 10
    Eun-young Cho, Hyung-jin Kim, Channy Park, Hong-seob So, Rae Kil Park, Haak Cheoul Kim, Impact of Nucleotide Mutations at the HNF3- and HNF4-Binding Sites in Enhancer 1 on Viral Replication in Patients with Chronic Hepatitis B Virus Infection, Gut and Liver, 2013, 7, 5, 569

    CrossRef

  11. You have free access to this content11
    George V. Papatheodoridis, Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?, Liver International, 2013, 33,
  12. 12
    C. M. N. Croagh, S. J. Bell, S. Locarnini, P. V. Desmond, Assessment of chronic hepatitis B: the importance of hepatitis B virus DNA testing, Internal Medicine Journal, 2012, 42, 2
  13. 13
    T. Stroffolini, A. Spadaro, V. Di Marco, G. Scifo, M. Russello, G. Montalto, G. Bertino, L. Surace, B. Caroleo, G. Foti, V. Portelli, S. Madonia, M. Sapienza, L. Cosco, P. Frugiuele, A. Galdieri, N. Brandolino, R. Siciliano, S. Bruno, P.L. Almasio, Current practice of chronic hepatitis B treatment in Southern Italy, European Journal of Internal Medicine, 2012, 23, 5, e124

    CrossRef

  14. 14
    EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection, Journal of Hepatology, 2012, 57, 1, 167

    CrossRef

  15. 15
    George V. Papatheodoridis, Spilios Manolakopoulos, Yun-Fan Liaw, Anna Lok, Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review, Journal of Hepatology, 2012, 57, 1, 196

    CrossRef

  16. 16
    Chih-Lin Lin, Tai-Chung Tseng, Tung-Hung Su, Chun-Jen Liu, Pei-Jer Chen, Ming-Yang Lai, Ding-Shinn Chen, Jia-Horng Kao, Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission, Hepatology International, 2012, 6, 3, 598

    CrossRef

  17. 17
    Runu Chakravarty, Role of molecular diagnostics in the management of viral hepatitis B, Expert Opinion on Medical Diagnostics, 2012, 6, 5, 395

    CrossRef

  18. 18
    Y.-C. Chen, S.-F. Huang, C.-M. Chu, Y.-F. Liaw, Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion, Journal of Viral Hepatitis, 2012, 19, 2
  19. 19
    F. M. Sanai, A. Helmy, K. I. Bzeizi, M. A. Babatin, A. Al-Qahtani, H. A. Al-Ashgar, A. S. Al-Mdani, A. Al-Akwaa, S. Almutharea, M. Q. Khan, A. S. Alghamdi, T. Farah, W. Al-Hamoudi, M. Saadeh, A. A. Abdo, Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B, Journal of Viral Hepatitis, 2011, 18, 7
  20. 20
    Maximilian Lee, Emmet B. Keeffe, Hepatitis B: Modern End Points of Treatment and the Specter of Viral Resistance, Gastroenterology Clinics of North America, 2011, 40, 3, 495

    CrossRef

  21. 21
    James Fung, Wai-Kay Seto, Ching-Lung Lai, John Yuen, Danny Ka-Ho Wong, Man-Fung Yuen, Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy, Journal of Hepatology, 2011, 54, 2, 195

    CrossRef

  22. 22
    L. Castéra, P.-H. Bernard, B. Le Bail, J. Foucher, P. Trimoulet, W. Merrouche, P. Couzigou, V. de Lédinghen, Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers, Alimentary Pharmacology & Therapeutics, 2011, 33, 4
  23. 23
    A. M. Ippolito, G. A. Niro, R. Fontana, G. Lotti, D. Gioffreda, M. R. Valvano, A. Iacobellis, L. Di Mauro, T. Stroffolini, A. Andriulli, Unawareness of HBV infection among inpatients in a Southern Italian hospital, Journal of Viral Hepatitis, 2011, 18, 7
  24. 24
    H. Lik-Yuen Chan, G. Lai-Hung Wong, C.-H. Tse, H.-Y. Chan, V. Wai-Sun Wong, Viral Determinants of Hepatitis B Surface Antigen Seroclearance in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients, Journal of Infectious Diseases, 2011, 204, 3, 408

    CrossRef

  25. 25
    Michelle Lai, Yun-Fan Liaw, Chronic Hepatitis B: Past, Present, and Future, Clinics in Liver Disease, 2010, 14, 3, 531

    CrossRef

  26. 26
    James Fung, Ching-Lung Lai, Man-Fung Yuen, Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B, Expert Review of Anti-infective Therapy, 2010, 8, 6, 717

    CrossRef

  27. 27
    Chia–Ming Chu, Yi–Cheng Chen, Dar–In Tai, Yun–Fan Liaw, Level of Hepatitis B Virus DNA in Inactive Carriers With Persistently Normal Levels of Alanine Aminotransferase, Clinical Gastroenterology and Hepatology, 2010, 8, 6, 535

    CrossRef

  28. 28
    William Graham Earnshaw Cooksley, Natural history of chronic hepatitis B: extending the REVEAL study, Liver International, 2010, 30, 8
  29. 29
    Yun-Fan Liaw, Antiviral therapy of chronic hepatitis B: Opportunities and challenges in Asia, Journal of Hepatology, 2009, 51, 2, 403

    CrossRef

  30. 30
    George V. Papatheodoridis, Spilios Manolakopoulos, EASL clinical practice guidelines on the management of chronic hepatitis B: The need for liver biopsy, Journal of Hepatology, 2009, 51, 1, 226

    CrossRef

  31. 31
    Dar-In Tai, Shi-Ming Lin, I-Shyan Sheen, Chia-Ming Chu, Deng-Yn Lin, Yun-Fan Liaw, Long-term outcome of hepatitis B e antigen–negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time, Hepatology, 2009, 49, 6
  32. 32
    George V. Papatheodoridis, Emanuel K. Manesis, Spilios Manolakopoulos, Ioannis S. Elefsiniotis, John Goulis, Athanasios J. Archimandritis, Reply:, Hepatology, 2009, 49, 2
  33. 33
    Emanuel K. Manesis, The natural history of chronic HBV infection, Current Hepatitis Reports, 2009, 8, 1, 10

    CrossRef

  34. 34
    George V. Papatheodoridis, Emanuel K. Manesis, Spilios Manolakopoulos, Ioannis S. Elefsiniotis, John Goulis, John Giannousis, Antonios Bilalis, Georgia Kafiri, Dimitrios Tzourmakliotis, Athanasios J. Archimandritis, Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen–negative chronic hepatitis B virus infection?, Hepatology, 2008, 48, 5
  35. 35
    Yun-Fan Liaw, Natural History of Chronic Hepatitis B Virus Infection,